Flosonics Medical announces that its FloPatch wearable Doppler ultrasound device has earned an Innovative Technology contract from Vizient, the nation’s largest provider-driven healthcare performance improvement company.
Hospital experts on one of Vizient’s client-led councils reviewed FloPatch and recognized its potential to enhance fluid management decisions and improve patient outcomes in sepsis care. These contracts emerge from Vizient’s Innovative Technology Program, where councils evaluate products for their ability to boost clinical care, patient safety, healthcare worker safety, or operational efficiency.
Transforming Fluid Management at the Bedside
“FloPatch was designed to give frontline clinicians the hemodynamic data they need to make better fluid decisions, faster, and without additional specialized training or equipment,” states Joe Eibl, CEO and co-founder of Flosonics Medical. “This Vizient Innovative Technology contract validates what hospitals have experienced firsthand: that bringing objective, real-time fluid responsiveness data to the bedside can transform sepsis care delivery. Through this contract, we’re excited to bring enhanced access of this technology to patients who need it.”
Addressing Key Challenges in Sepsis Treatment
FloPatch stands as the first FDA-approved, wireless, wearable Doppler ultrasound device for assessing blood flow. Clinicians use these assessments to tailor intravenous fluid management for sepsis patients and other critical cases. Research indicates nearly one-third of septic shock patients fail to respond to extra IV fluids, yet bedside tools for fluid responsiveness have been limited.
Dynamic fluid assessments with FloPatch reduce needs for mechanical ventilation and renal replacement therapy, shorten ICU stays, and link to lower mortality rates. The device delivers objective, real-time data in minutes, helping clinicians decide precisely when fluids help or harm.
Scalable Solution for Health Systems
Unlike traditional methods requiring specialized training or equipment, FloPatch empowers any bedside clinician to perform assessments. This scalability supports standardization across emergency departments and ICUs, aiding compliance with sepsis protocols like CMS SEP-1.
“After a review of the FloPatch Wearable Doppler Ultrasound, Vizient’s client-led council agreed this technology offers a unique benefit over other products available in the market today and recommended it for an Innovative Technology contract. We are pleased to award this new contract to Flosonics,” says Kelly Flaharty, associate vice president of contract operations for Vizient.
Vizient serves academic medical centers, pediatric facilities, community hospitals, integrated networks, and non-acute providers, managing over $156 billion in annual purchasing volume.
About Flosonics Medical
Flosonics Medical develops innovative ultrasound technologies to advance patient care. Founded in 2015, the company focuses on technology-driven solutions and clinical research. Learn more at www.flosonicsmedical.com.
